Hereditary Angioedema
📧 Sign up to get email alerts when something new happens for Hereditary Angioedema.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Andembry (garadacimab) — CSL Behring GmbH
European Medicines Agency authorises Andembry (garadacimab) for hereditary angioedema.
-
CLINICAL_TRIALS trial_result · 2026-08-17Clinical Trial Results: Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II [Phase 2]
A Phase 2 dose-ranging study evaluating oral PHA-022121 for prophylaxis of angioedema attacks in patients with hereditary angioedema (Types …
-
EMA approval · 2026-08-06EMA Authorised: Firazyr (icatibant) — Takeda Pharmaceuticals International AG
Authorised status for Firazyr (icatibant) by EMA for hereditary angioedema; MAH Takeda Pharmaceuticals International AG.
-
CLINICAL_TRIALS trial_result · 2026-08-05Clinical Trial Results: Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II [Phase 3]
Phase 3 open-label trial assessing safety, pharmacokinetics, and efficacy of sebretalstat (KVD900) in pediatric patients with hereditary ang…
-
EMA approval · 2026-08-03EMA Authorised: Takhzyro (lanadelumab) — Takeda Pharmaceuticals International AG Ireland Branch
EMA has authorised Takhzyro (lanadelumab) by Takeda for hereditary angioedema with accelerated assessment and orphan designation.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-21EMA Authorised: Takhzyro (lanadelumab) — Takeda Pharmaceuticals International AG Ireland Branch
EU authorization for Takhzyro (lanadelumab) by Takeda for hereditary angioedema, with orphan designation and accelerated assessment.
-
EMA approval · 2026-07-14EMA Authorised: Ekterly (sebetralstat) — Kalvista Pharmaceuticals (Ireland) Limited
Ekterly (sebetralstat) has been authorised in the EU for hereditary angioedema, with Kalvista Pharmaceuticals (Ireland) Limited as the marke…
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Update: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial [Phase 3]
Phase 3 PK subtrial in adolescents with hereditary angioedema participating in the KVD900-302 trial has completed.
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) [Phase 3]
Open-label extension trial assessing long-term safety of KVD900 (sebentralstat) for on-demand treatment of angioedema attacks in adolescents…
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Results: Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks [Phase 3]
Phase 3 results for garadacimab (CSL312) in long-term prophylaxis of hereditary angioedema indicate safety and efficacy outcomes from comple…
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Results: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema [Phase 3]
Phase 3 trial results for CSL312_3003 safety and pharmacokinetics in children aged 2 to 11 with hereditary angioedema (HAE) have been comple…
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Update: Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks [Phase 3]
Phase 3 trial update on garadacimab (CSL312) for prophylaxis of hereditary angioedema shows completed study with posted results.
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Update: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema [Phase 3]
Phase 3 safety and pharmacokinetic trial of CSL312_3003 in children aged 2 to 11 with hereditary angioedema; study completed with results po…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of ADX-324 in healthy volunteers and patient…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia
The update describes a study of lanadelumab in teenagers and adults with hereditary angioedema in the Kingdom of Saudi Arabia, which is curr…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: STOP-HAE: A Phase 3 Study of ADX-324 in HAE [Phase 3]
A Phase 3 trial (STOP-HAE) evaluating ADX-324 for hereditary angioedema (types I and II) is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Phase 2 in Adult Subjects With Hereditary Angioedema [Phase 2]
A Phase 2 clinical trial in adults with hereditary angioedema is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Donidalorsen Treatment in Children With Hereditary Angioedema [Phase 3]
Phase 3 trial evaluating donidalorsen for hereditary angioedema in children is currently recruiting.
-
EMA approval · 2026-04-16EMA Authorised: Icatibant Accord (icatibant acetate) — Accord Healthcare S.L.U.
The EMA authorised Icatibant Accord (icatibant acetate) for hereditary angioedema, with Accord Healthcare S.L.U. as the marketing authorizat…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Survey of Lanadelumab in Participants With Hereditary Angioedema
A clinical trial update describing a survey of lanadelumab in participants with hereditary angioedema; the study is currently active but not…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Study of Navenibart in Participants With Hereditary Angioedema [Phase 3]
A Phase 3 clinical trial to evaluate the safety and efficacy of Navenibart in participants with hereditary angioedema; the study is currentl…
-
EMA approval · 2026-04-01EMA Authorised: Firazyr (icatibant) — Takeda Pharmaceuticals International AG
The European Medicines Agency authorised Firazyr (icatibant) by Takeda Pharmaceuticals International AG for hereditary angioedema.
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab [Phase 4]
A Phase 4 safety study evaluating switching to garadacimab in subjects aged 12 years and older with hereditary angioedema is currently recru…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema [NA]
A Takeda-sponsored clinical study aims to evaluate C1-inhibitor function as a diagnostic test for hereditary angioedema.
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
Takeda-sponsored clinical study evaluating lanadelumab for hereditary angioedema (HAE) in Poland has completed.